Previous 10 | Next 10 |
Summary ARK Genomic Revolution ETF invests in small-cap and mid-cap companies engaged in genomic revolution, i.e., in the research of genomic sequencing, analysis, synthesis, or instrumentation. Alpha-generating stocks ARKG selects from time to time and backs for a longer time period ha...
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25 th Annual Needham Growth Conference on Wednesday, January 11, 2023 and will host a fireside chat at 1:30 pm ET. A webcast and replay of the fireside chat will be availab...
Summary Accolade went public in mid-2020, raising around $220 million in a U.S. IPO. The firm provides healthcare management capabilities to enterprises and other client types. ACCD has grown revenue but continues to generate significant operating losses. I'm on Hold for ACCD un...
SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes. In conjunction, the company w...
Accolade Champions Health Equity and Welcomes FOLX Health to Trusted Partner Ecosystem at HLTH 2022 PR Newswire Chief Medical Officer Dr. Shantanu Nundy and Dr. Jay Bhatt , Managing Director at Deloitte, explore the role of employers in removing barriers to equ...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
Summary Accolade outperformed in Q2 2023 on another strong quarter of double-digit revenue growth. Full-year guidance has moved slightly higher, but there remains ample room for more upward revisions. With the fundamentals firmly intact despite the ongoing macro challenges, th...
Accolade Inc. (ACCD) Q2 2023 Earnings Conference Call October 06, 2022, 04:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of I...
Accolade press release ( NASDAQ: ACCD ): Q2 GAAP EPS of -$0.66 beats by $0.06 . Revenue of $87.6M (+19.5% Y/Y) beats by $4.74M . For the fiscal third quarter ending November 30, 2022, we expect: Revenue between $86 million and $88 million vs $89.3M Co...
Fiscal second quarter 2023 revenue of $87.6 million, a 20% increase compared to fiscal second quarter 2022 revenue of $73.3 million SEATTLE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
NEW YORK, NY / ACCESSWIRE / July 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ:ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information ...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 50.0% to $0.495 on volume of 360,218,139 shares NVIDIA Corporation (NVDA) fell 0.4% to $123.54 on volume of 307,578,749 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) rose 8.1% to $0.3343 on vol...